RNA (Avidity Biosciences) Accounts Payable & Accrued Expense : $69.52 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Avidity Biosciences Accounts Payable & Accrued Expense?

Avidity Biosciences's quarterly accounts payable & accrued expense increased from Jun. 2024 ($40.92 Mil) to Sep. 2024 ($49.63 Mil) and increased from Sep. 2024 ($49.63 Mil) to Dec. 2024 ($69.52 Mil).

Avidity Biosciences's annual accounts payable & accrued expense increased from Dec. 2022 ($32.57 Mil) to Dec. 2023 ($34.34 Mil) and increased from Dec. 2023 ($34.34 Mil) to Dec. 2024 ($69.52 Mil).

Avidity Biosciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Avidity Biosciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avidity Biosciences Accounts Payable & Accrued Expense Chart

Avidity Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

7.75

14.09

32.57

34.34

69.52

Avidity Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															34.34	37.33	40.92	49.63	69.52

Avidity Biosciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Avidity Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avidity Biosciences Inc (NAS:RNA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121

Website

https://www.aviditybiosciences.com

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Executives

Michael F Maclean	officer: Chief Financial Officer	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
W. Michael Flanagan	officer: Chief Technical Officer	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Teresa Mccarthy	officer: Chief Human Resources Officer	10975 N TORREY PINES RD #150, LA JOLLA CA 92037
Sarah Boyce	director, officer: President and CEO	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Arthur A Levin	officer: Chief Scientific Officer	1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Tamar Thompson	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Eric Mosbrooker	director	C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jean Jinsun Kim	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Jae B. Kim	officer: Chief Medical Officer	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Kaye Edward M. Md	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director, 10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Roderick Wong	director, 10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014